Equities analysts expect Kezar Life Sciences Inc (NASDAQ:KZR) to report earnings per share of ($0.21) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kezar Life Sciences’ earnings, with the lowest EPS estimate coming in at ($0.22) and the highest estimate coming in at ($0.19). Kezar Life Sciences posted earnings per share of ($0.48) during the same quarter last year, which would indicate a positive year over year growth rate of 56.3%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, November 4th.
According to Zacks, analysts expect that Kezar Life Sciences will report full-year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($0.95) to ($0.90). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.06) to ($0.95). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Kezar Life Sciences.
Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.04.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bellevue Group AG boosted its position in Kezar Life Sciences by 20.5% during the second quarter. Bellevue Group AG now owns 4,241,940 shares of the company’s stock worth $21,973,000 after purchasing an additional 723,051 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Kezar Life Sciences by 176.5% during the 1st quarter. Victory Capital Management Inc. now owns 1,370,027 shares of the company’s stock worth $5,973,000 after acquiring an additional 874,576 shares in the last quarter. Cormorant Asset Management LP bought a new position in shares of Kezar Life Sciences in the 2nd quarter valued at approximately $6,734,000. Candriam Luxembourg S.C.A. acquired a new stake in Kezar Life Sciences in the 2nd quarter worth approximately $3,108,000. Finally, Alyeska Investment Group L.P. boosted its position in Kezar Life Sciences by 140.1% during the second quarter. Alyeska Investment Group L.P. now owns 588,502 shares of the company’s stock worth $3,048,000 after purchasing an additional 343,383 shares during the period. 50.15% of the stock is currently owned by institutional investors.
Kezar Life Sciences stock traded up $0.34 during mid-day trading on Friday, reaching $5.63. 194,776 shares of the company’s stock traded hands, compared to its average volume of 442,974. The stock has a 50 day moving average of $4.87 and a two-hundred day moving average of $4.94. Kezar Life Sciences has a 12-month low of $2.18 and a 12-month high of $9.79. The company has a market cap of $260.42 million, a price-to-earnings ratio of -3.75 and a beta of 0.12.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
Featured Article: Portfolio Manager
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.